The following pages link to Meinhard Kieser (Q66448):
Displaying 50 items.
- Optimization of the two‐stage group sequential three‐arm gold‐standard design for non‐inferiority trials (Q66449) (← links)
- A variational approach to optimal two‐stage designs (Q124479) (← links)
- The adoptr Package: Adaptive Optimal Designs for Clinical Trials in R (Q124480) (← links)
- Configural frequency analysis and association analyses in contingency tables (Q956776) (← links)
- Including long- and short-term data in blinded sample size recalculation for binary endpoints (Q957163) (← links)
- Consistency-adjusted alpha allocation methods for a time-to-event analysis of composite endpoints (Q1623485) (← links)
- (Q1818600) (redirect page) (← links)
- Procedures for testing multiple endpoints in clinical trials: an overview (Q1818602) (← links)
- An expected power approach for the assessment of composite endpoints and their components (Q2361228) (← links)
- Supporting information blinded sample size recalculation in multicentre trials with normally distributed outcome (Q2786184) (← links)
- Assessing additional benefit in noninferiority trials (Q2792768) (← links)
- Optimal adaptive two-stage designs for phase II cancer clinical trials (Q2858002) (← links)
- Curtailment in single-arm two-stage phase II oncology trials (Q2912001) (← links)
- Test-compatible confidence intervals for adaptive two-stage single-arm designs with binary endpoint (Q3134246) (← links)
- Adjustment for exploratory cut‐off selection in randomized clinical trials with survival endpoint (Q3299056) (← links)
- Integrated evaluation of targeted and non‐targeted therapies in a network meta‐analysis (Q3299077) (← links)
- (Q4260090) (← links)
- (Q4260092) (← links)
- On the Use of the Upper Confidence Limit for the Variance from a Pilot Sample for Sample Size Determination (Q4353943) (← links)
- A unifying approach for confidence intervals and testing of equivalence and difference (Q4364964) (← links)
- APPROXIMATE SAMPLE SIZES FOR TESTING HYPOTHESES ABOUT THE RATIO AND DIFFERENCE OF TWO MEANS (Q4512644) (← links)
- A closer look at the effect of preliminary goodness‐of‐fit testing for normality for the one‐sample <i>t</i>‐test (Q4561342) (← links)
- Improving the Flexibility and Efficiency of Phase II Designs for Oncology Trials (Q4649069) (← links)
- Sample size calculations for noninferiority trials with Poisson distributed count data (Q4917514) (← links)
- Sample Size Calculation and Blinded Sample Size Recalculation in Clinical Trials Where the Treatment Effect is Measured by the Relative Risk (Q4929234) (← links)
- Configural Frequency Analysis (CFA) Revisited — a New Look at an Old Approach (Q4944479) (← links)
- Optimal sample size allocation and go/no‐go decision rules for phase II/III programs where several phase III trials are performed (Q4967100) (← links)
- A note on the shape of sample size functions of optimal adaptive two-stage designs (Q5079909) (← links)
- Methods and Applications of Sample Size Calculation and Recalculation in Clinical Trials (Q5115628) (← links)
- A Bootstrap Procedure for Adaptive Selection of the Test Statistic in Flexible Two-Stage DesignsThis paper is based on a presentation given at the Workshop “Frontiers in Adaptive Designs”, 17.–18. 5. 2001, Vienna/Austria. (Q5121860) (← links)
- A Comparison of Procedures for Adaptive Choice of Location Tests in Flexible Two-Stage Designs (Q5122370) (← links)
- Blinded Sample Size Recalculation for Normally Distributed Outcomes Using Long- and Short-term Data (Q5122423) (← links)
- Sample Size Recalculation in Internal Pilot Study Designs: A Review (Q5122838) (← links)
- Monitoring Continuous Long-Term Outcomes in Adaptive Designs (Q5460707) (← links)
- A note on change point estimation in dose-response trials (Q5941551) (← links)
- Utility‐based optimization of phase II/III programs (Q5978234) (← links)
- Optimal designs for phase II/III drug development programs including methods for discounting of phase II results (Q5978235) (← links)
- Optimal planning of phase II/III programs for clinical trials with multiple endpoints (Q5978237) (← links)
- Optimal planning of adaptive two‐stage designs (Q5981703) (← links)
- Optimization of adaptive designs with respect to a performance score (Q6068637) (← links)
- Monotonicity conditions for avoiding counterintuitive decisions in basket trials (Q6089920) (← links)
- Using independent cross‐sectional survey data to predict post‐migration health trajectories among refugees by estimating transition probabilities and their variances (Q6089925) (← links)
- Categories, components, and techniques in a modular construction of basket trials for application and further research (Q6091664) (← links)
- Using real-world data to predict health outcomes -- the prediction design: application and sample size planning (Q6594187) (← links)
- Point estimation, confidence intervals, and \(P\)-values for optimal adaptive two-stage designs with normal endpoints (Q6618447) (← links)
- Simulation and data-generation for random-effects network meta-analysis of binary outcome (Q6624698) (← links)
- A variational approach to optimal two-stage designs (Q6625214) (← links)
- What makes a biostatistician? (Q6625673) (← links)
- Comments on ``Adaptive sample size modification in clinical trials: start small then ask for more?'' (Q6627273) (← links)
- A new conditional performance score for the evaluation of adaptive group sequential designs with sample size recalculation (Q6627407) (← links)
